Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.

摘要: ABSTRACT Objective Atypical neuroleptics, including risperidone, are used to treat children with autism, despite limited efficacy and safety data. Many clinicians believe that risperidone will not induce dyskinesias in children. The authors investigated open treatment autism included findings on dyskinesias. Method sample 22 outpatients (mean age = 7.1 years) diagnosed ( DSM-IV ). Treatment consisted of a 1-month short-term phase followed by 6-month long-term phase. At the end phase, drug was discontinued, need for further occurrence withdrawal were assessed. Measures Clinical Global Impressions (CGI), Children's Psychiatric Rating Scale (CPRS), Abnormal Involuntary Movement Scale. Results mean dosage 1.2 mg/day. Overall, had significant clinical improvement as assessed CPRS CGI. Untoward effects sedation, increased appetite, weight gain. Two 13 (15.4%) treated developed mild, reversible when discontinued. No child risperidone. Conclusions Risperidone shows promise autism. However, noted. Further assessment risk risperidone-related is indicated.